Age-Related Macular Degeneration Market to Surpass US$ Billion by 2033

Innovations in Biologics, Aging Populations, and Rising Vision Disorders Drive Market Expansion

According to the latest report by Renub Research, the Age-Related Macular Degeneration (AMD) Market is projected to grow from US$ 12.64 billion in 2024 to US$ 23.84 billion by 2033, expanding at a CAGR of 7.16% from 2025 to 2033. The rising geriatric population, advancements in biologics and gene therapies, and growing awareness about early-stage diagnosis are major contributors to this market’s robust expansion.

? Access the full report here: Age-Related Macular Degeneration Market Report

AMD: A Leading Cause of Vision Loss Worldwide

Age-Related Macular Degeneration is one of the leading causes of irreversible vision loss among people aged 50 and above. The disease progressively damages the macula, a critical part of the retina responsible for central vision, making everyday tasks like reading, driving, and recognizing faces difficult.

There are two main types of AMD:

Dry (atrophic) AMD – more common, progresses slowly.
Wet (neovascular) AMD – less common but more severe and fast-progressing.

With the global population rapidly aging, the prevalence of AMD is expected to rise significantly, thereby increasing the demand for effective diagnostic and therapeutic solutions.

Biologic Therapies and Gene Innovations Fuel Treatment Advancements

One of the most transformative developments in the AMD market has been the emergence of biologics and gene therapy. These innovations are offering new hope for patients, particularly those suffering from wet AMD.

Leading therapies such as:

Anti-VEGF (Vascular Endothelial Growth Factor) drugs, including Eylea (aflibercept), Lucentis (ranibizumab), and Beovu (brolucizumab)
Biosimilars for cost-effective treatment alternatives
Long-acting implants and gene therapies under clinical trials
are reshaping the therapeutic landscape. These treatments reduce macular swelling, inhibit abnormal blood vessel formation, and improve visual outcomes.

As a result, biologic drugs continue to dominate market share, and their continued development is expected to be a key driver of market growth over the next decade.

Growing Aging Population and Lifestyle Risks Amplify Disease Incidence

According to the United Nations, by 2030, 1 in 6 people globally will be over the age of 60, significantly increasing the vulnerable population for age-related disorders such as AMD.

Additionally, lifestyle-related factors such as smoking, obesity, cardiovascular issues, and poor nutrition are contributing to the earlier onset and faster progression of AMD. As more people develop risk factors earlier in life, early detection, and intervention become even more crucial, boosting demand for screening services and treatment options.

Diagnostics Segment Witnessing Growth Through Early Detection Tools

With increased emphasis on preventive healthcare and early diagnosis, the demand for advanced diagnostic technologies is rising. Key diagnostic tools include:

Optical Coherence Tomography (OCT)
Fluorescein Angiography
Fundus Photography
Amsler Grid tests

Modern clinics and hospitals are now integrating AI-based image recognition systems to detect early retinal changes before symptoms arise. These technologies enhance diagnostic speed and accuracy, ensuring patients begin therapy at the optimal stage for maximum efficacy.

Wet AMD Holds the Largest Market Share

Although dry AMD accounts for about 85–90% of all AMD cases, it is wet AMD that dominates the global market in terms of treatment revenue due to the availability of high-cost therapeutics and biologics.

Wet AMD is characterized by rapid vision deterioration caused by abnormal blood vessel growth under the retina. Anti-VEGF therapies, administered via intraocular injections, have become the standard of care and are regularly used in clinical settings across the globe.

Dry AMD, on the other hand, is currently managed with nutritional supplements (AREDS2 formula) and lifestyle interventions, but clinical trials for novel drugs and stem cell therapies are underway, signaling future revenue opportunities.

Distribution Channels: Hospitals and Specialized Eye Clinics Lead Demand

The primary end-users in the AMD market are:

Hospitals
Specialized ophthalmology clinics
Ambulatory surgery centers
Retail pharmacies and online platforms

Hospitals and eye clinics account for the highest number of AMD treatment procedures due to their access to sophisticated diagnostic tools and trained retina specialists. However, home care and online pharmacies are gaining traction with the rise in remote consultations and e-prescription services, especially in developed regions.

Regional Insights: North America Leads, Asia-Pacific Emerges as Fastest-Growing Region

North America

The United States dominates the global AMD market owing to:

High awareness and screening rates
Strong reimbursement frameworks
Presence of key players and FDA-approved therapies
Advanced healthcare infrastructure

Europe

Germany, the UK, and France lead the European market. Public health initiatives, combined with aging demographics and funding for retinal research, contribute to regional growth.

Asia-Pacific

This region is the fastest-growing, driven by:

Rising geriatric population
Increasing diabetes and cardiovascular conditions
Growing investment in healthcare infrastructure
Expanding access to ophthalmic care in China, Japan, and India

Middle East, Latin America, and Africa

Though currently underserved, these regions offer untapped potential, with non-profit programs, public-private partnerships, and mobile eye care services working to close the diagnosis and treatment gap.

Competitive Landscape: Innovation, Collaborations, and R&D Drive Market Leadership

The AMD market is highly competitive, with major pharmaceutical and biotech companies investing in clinical trials, strategic alliances, and product expansion. Partnerships between biotech startups and pharma giants are becoming common to speed up drug development and market penetration.

Leading Players in the Global AMD Market:

Regeneron Pharmaceuticals, Inc. (Eylea)
Roche/Genentech (Lucentis, Vabysmo)
Novartis AG
Bayer AG
Kodiak Sciences
Allergan/AbbVie
Graybug Vision
Samsung Bioepis
Biogen
Outlook Therapeutics

These companies are focused on creating longer-acting treatments, reduced injection frequencies, and less invasive drug delivery systems to improve patient compliance and reduce healthcare costs.

Market Outlook: Future Trends and Opportunities

Looking forward, the AMD market will be shaped by:

Emergence of biosimilars that lower treatment costs
Advancement in retinal gene therapy and stem cell therapy
Use of wearable eye health trackers and mobile apps for remote monitoring
Greater public health funding for vision screening programs

Moreover, the introduction of long-duration drug implants, port delivery systems, and sustained-release eye drops will redefine how AMD is treated in the coming years.

New Publish Report:

About Renub Research

Renub Research is a Market Research and Consulting Company with more than 15 years of experience, especially in international Business-to-Business Research, Surveys, and Consulting. We provide a wide range of business research solutions that help companies make better business decisions.

We partner with clients across all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele includes key players in Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture.

Our core team comprises experienced professionals with graduate, postgraduate, and Ph.D. qualifications in Finance, Marketing, Human Resources, Bio-Technology, Medicine, Information Technology, Environmental Science, and more.

Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com

? To access the complete report, visit:
? Age-Related Macular Degeneration Market Report